Cite
HARVARD Citation
Malvehy, J. et al. (2021). Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma. Journal for immunotherapy of cancer. 9 (3), p. . [Online].